

A G E N D A

3rd International Thoracic Oncology Congress Dresden (3rd ITOCD), Advances through Molecular Biology in Thoracic Cancer , September 13-15, 2012

Congress Venue:

The Westin Bellevue Hotel & Congress Center Dresden, Große Meissner Straße 15, 01097 Dresden, Germany

Registration:

Delegates Helping Desk (Westin Bellevue Dresden -Congress Center)

Opening Hours:

September 12, 2012 02:00 p.m. – 10:00 p.m.

September 13, 2012 – September 15, 2012 07:30 a.m. – 06:00 p.m.

Thursday, September 13, 2012

- 08:00 – 08:30 Opening remarks
- 08:30 – 09:15 Key note lecture on cancer biology
- Ectopic expression of protein elongation factors - a new Hallmark
 for lung and other cancers
- A.F. Gazdar, Dallas
- Targeting Tumor Angiogenesis:
- Molecular Biology and Clinical Practice
- Chairs: N. Saijo, Tokyo /C. Manegold, Mannheim
- 09:15 – 09:30 Angiogenesis and the metastatic process
 F. Bussolino, Torino
- 09:30 – 09:45 Angiogenesis and biomarker-profiling
 J. Heymach, Houston
- 09:45 – 10:00 Molecular Imaging and anti-angiogenic therapy
 C. Fink, Mannheim
- 10:00 – 10:15 Mechanism of resistance to anti-angiogenic agents
 M. Edelman, Baltimore
- 10:15 – 10:30 Integrin inhibitors
 S. Peters, Lausanne
- 10:30 – 10:45 Anti-angiogenic TKI's
 J.Y. Doulliard, Nantes
- 10:45 – 11:15 Discussant: A. B. Sandler, Portland
- 11:30 – 12:30 Boehringer-Ingelheim Symposium
- 12:30 - 13:30 open
- 13:30 – 14:15 Abbott Symposium

Thursday, September 13, 2012

Novel Agents (1)

Chairs: W. Eberhardt, Essen / T. Le Chevalier, Paris

- | | |
|---------------|--|
| 14:30 – 14:45 | Novel targets and therapies
P.A. Jänne, Boston |
| 14:45 – 15:00 | Heat shock protein targeting agents
K. O'Byrne, Dublin |
| 15:00 – 15:15 | PARP1-inhibition
Thomas Helleday (Oxford) |
| 15:15 – 15:30 | Dendritic cell recruiters and activators
A. Y. Chang, Singapore |
| 15:30– 15:45 | Vaccine therapy
J. Vansteenkiste, Leuven |
| 15:45 – 16:00 | C-met inhibition in lung cancer
S. Novello, Torino |
| 16:00 – 16:30 | Discussant: G. Giaccone, Bethesda |
| 19:30 - 23:00 | Faculty Dinner |

Friday, September 14, 2012

08:00 – 08:45 Mannheim Lilly Oncology Lecture

Genomics in Lung Cancer
R. Thomas, Köln

Targeting the Epidermal Growth Factor Receptor (EGFR):

Molecular Biology and Clinical Practice

Chairs: A.F. Gazdar, Dallas / T. Mok, Hong Kong

09:00- 09:30 Enhancing EGFR-directed therapies through a novel research platform
D. Gandara, Davis

09:30 - 09:45 Mechanisms of drug resistance and subsequent therapies in EGFR-TKI failure
Stahel, R. , Zurich

09:45 – 10:00 Genomic heterogeneity between primary tumor and its metastases
W.-Z. Zhong, Guangzhou

10:00 – 10:15 Mutation specific antibodies to detect EGFR-status in small biopsies and cytology specimens
I. Petersen, Jena

10:15 – 10:30 Predictive markers in thoracic oncology
F. A. Shepherd, Toronto

10:30 – 10:45 Second generation of EGFR-TKI inhibitors
F. Cappuzzo, Livorno

10:45 – 11:00 EGFR-targeting antibodies: How to predict efficacy?
R. Pirker, Vienna

- 11:00 – 11:15 Combination of EGFR-TKI and EGFR- MoAb:
Rationale and early results
R. Dziadziusko, Gdansk
- 11.15 – 11.45 Discussant: T.J. Lynch, New Haven
- 11:45 – 12:15 BREAK
- 12:15 – 13:15 PRESIDENTIAL SYMPOSIUM
- 13.30 – 14.30 Hoffmann- La Roche-Symposium

Friday, September 14, 2012

Gene Expression/Proteomics/Tumor Histology Guided Therapy

Chairs: N. van Zandwijk, Sydney / J. Niklinski, Bialystok

- 14.45 – 15.15 Proteomics: Ready for prime time?
D. Carbone, Nashville
- 15.15 – 15.30 The role of immunohistochemistry in prognosis and prediction
F. Hirsch, Denver
- 15.30 – 15.45 Techniques to diagnose ALK-Translocation
P.-C. Yang, Taiwan
- 15.45 – 16:00 Genomic characterization and targeted therapies for squamous
cell carcinoma of the lung
P. Hammerman, Boston
- 16:00 – 16:15 Treatment selection by ERCC1 expression /RRM1 expression:
The MADEiT and the EPIC study
G. Simon, Charleston
- 16.15 – 16:30 Characterization of adenoma-carcinoma
E. Thunnissen, Amsterdam
- 16:30 – 16:45 Biomarker –driven studies
B. Besse, Villejuif
- 16:45 – 17:15 Discussant: K. Kerr, Aberdeen

19:30 Grand Evening Event

Saturday, September 15, 2012

08:00 – 08:45 Meet the Professor Session

1. Management of bone metastasis: P. Harper, London
2. Procurement, Processing and interpretation of small biopsy specimen.
M. Papotti, Torino

Novel Agents (2)

Chairs: J.S. Lee, Seoul / P. Bunn, Denver

09:00 – 09:15 Window of opportunity trials for targeted therapies
M. Kris, New York

09:15 – 09:30 AKT, MAPK, MEK-inhibitors
A. Adjei, Buffalo

09:30 – 09:45 ALK, MET-inhibitors
L. Crino, Perugia

09:45 – 10:00 SRC-targeting agents
O. Gautschi, Bern

10:00 – 10:15 IGFR-inhibitors : End of a targeted therapy ?
S. Ramalingam, Atlanta

10:15 – 10:30 Apoptotic agents
D. Fennell, Belfast

10:30 – 10:45 NCI-Canada Clinical trials investigating
targeted therapies
G. Goss, Ottawa

10:45 – 11:15 Discussant: L. Paz-Ares, Sevilla

11.15 – 11.45 BREAK

Stand: 18.04.2012

Saturday, September 15, 2012

Tabacco Control and Lung Cancer Prevention

Chairs: P. Postmus, Amsterdam/Y.L. Wu, Guangzhou

- | | |
|---------------|--|
| 11:45 – 12:00 | Implementation of smoking cessation: achievements and hurdles
J. Jassem, Gdansk |
| 12:00 – 12:15 | Smoking cessation efforts in Asia
C. Zhou, Shanghai |
| 12:15 – 12:30 | Lung Cancer survival-regional differences
C. M. Dresler, Little Rock |
| 12:30 – 12:45 | Chemoprevention: Lessons from randomized trials
Y. E. Miller, Denver |
| 12:45 – 13:00 | Molecular mechanism of chemopreventive compounds and novel approaches to assess efficacy
F. R. Khuri, Atlanta |
| 13:00 – 13:15 | Incorporating tobacco control into lung cancer screening programs
P. Boffetta, New York |
| 13:15 – 14:00 | BREAK |

Saturday, September 15, 2012

2012 Challenges in Thoracic Oncology (I)

Chairs: D. H. Grunenwald, Paris / K. Syrigos, Athens

- | | |
|---------------|--|
| 14:15 – 14:30 | New TNM classification: Achievements and hurdles
P. Goldstraw, London |
| 14:30 - 14:45 | Post-operative PET/CT for early detection of NSCLC recurrence
S. Schönberg, Mannheim |
| 14.45 - 15.00 | EBUS and EUS for N-staging
F. Herth, Heidelberg |
| 15:00 – 15:15 | Lung cancer in never smokers – prognostic and therapeutic implications
K. Park, Seoul |
| 15:15 – 15:30 | Is there a role of induction therapy?
P. van Schil, Antwerp |
| 15:30 – 15:45 | Malignant pleural mesothelioma: P/D vs EPP
W. Weder, Zurich |
| 15:45 – 16:15 | BREAK |

Saturday, September 15, 2012

2012 Challenges in Thoracic Oncology (II)

Chairs: F. Mornex, Lyon / N. Thatcher, Manchester

- | | |
|---------------|---|
| 16:15 – 16:30 | Stereotactic ablative radiation therapy (SABR) for NSCLC:
Patient selection and fractionation regimes
S. Senan, Amsterdam |
| 16:30 – 16:45 | New radiotherapy techniques
U. Ricardi, Torino |
| 16:45 – 17:00 | Potential toxicity of PCI
F. Wenz, Mannheim |
| 17.00 - 17.15 | Update of thymoma management
A. Marx, Mannheim |
| 17:15 – 17:30 | Clinical approaches to K-ras mutant NSCLC
E. Smith, Amsterdam |
| 17:30 -17:45 | Biomarkers in malignant pleural mesothelioma and treatment
prediction
V. Surmont, Gent |
| 17:45 – 18:00 | Is the treatment of SCLC heading through new pathways?
A. Ardizzoni, Parma |
| 18:00 | Closing Remarks
C. Manegold, Mannheim |